Biosimilar Insulin-EMEA Market Status and Trend Report 2013-2023

Date: December 17, 2017
Pages: 135
Price:
US$ 3,480.00
Publisher: MIReports Co., Limited
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: B0413983BA4EN
Leaflet:

Download PDF Leaflet

Biosimilar Insulin-EMEA Market Status and Trend Report 2013-2023
Report Summary

Biosimilar Insulin-EMEA Market Status and Trend Report 2013-2023 offers a comprehensive analysis on Biosimilar Insulin industry, standing on the readers’ perspective, delivering detailed market data and penetrating insights. No matter the client is industry insider, potential entrant or investor, the report will provides useful data and information. Key questions answered by this report include:

Whole EMEA and Regional Market Size of Biosimilar Insulin 2013-2017, and development forecast 2018-2023
Main market players of Biosimilar Insulin in EMEA, with company and product introduction, position in the Biosimilar Insulin market
Market status and development trend of Biosimilar Insulin by types and applications
Cost and profit status of Biosimilar Insulin, and marketing status
Market growth drivers and challenges

The report segments the EMEA Biosimilar Insulin market as:

EMEA Biosimilar Insulin Market: Regional Segment Analysis (Regional Consumption Volume, Consumption Volume, Revenue and Growth Rate 2013-2023):

Europe
Middle East
Africa

EMEA Biosimilar Insulin Market: Product Type Segment Analysis (Consumption Volume, Average Price, Revenue, Market Share and Trend 2013-2023):

Rapid Acting Insulins
Short Acting Insulins
Intermediate Insulins
Long Lasting Insulins

EMEA Biosimilar Insulin Market: Application Segment Analysis (Consumption Volume and Market Share 2013-2023; Downstream Customers and Market Analysis)

Hospital
Clinic
Medical Center

EMEA Biosimilar Insulin Market: Players Segment Analysis (Company and Product introduction, Biosimilar Insulin Sales Volume, Revenue, Price and Gross Margin):

Pfizer
Biogenomics
Eli Lilly
Gan&Lee Pharmaceuticals
Geropharm
Julphar Gulf Pharmaceutical Industries
Paras Biopharmaceuticals
Samsung Bioepis
Sedico
Wockhardt
Teva Pharmaceuticals

In a word, the report provides detailed statistics and analysis on the state of the industry; and is a valuable source of guidance and direction for companies and individuals interested in the market.

CHAPTER 1 OVERVIEW OF BIOSIMILAR INSULIN

1.1 Definition of Biosimilar Insulin in This Report
1.2 Commercial Types of Biosimilar Insulin
  1.2.1 Rapid Acting Insulins
  1.2.2 Short Acting Insulins
  1.2.3 Intermediate Insulins
  1.2.4 Long Lasting Insulins
1.3 Downstream Application of Biosimilar Insulin
  1.3.1 Hospital
  1.3.2 Clinic
  1.3.3 Medical Center
1.4 Development History of Biosimilar Insulin
1.5 Market Status and Trend of Biosimilar Insulin 2013-2023
  1.5.1 EMEA Biosimilar Insulin Market Status and Trend 2013-2023
  1.5.2 Regional Biosimilar Insulin Market Status and Trend 2013-2023

CHAPTER 2 EMEA MARKET STATUS AND FORECAST BY REGIONS

2.1 Market Status of Biosimilar Insulin in EMEA 2013-2017
2.2 Consumption Market of Biosimilar Insulin in EMEA by Regions
  2.2.1 Consumption Volume of Biosimilar Insulin in EMEA by Regions
  2.2.2 Revenue of Biosimilar Insulin in EMEA by Regions
2.3 Market Analysis of Biosimilar Insulin in EMEA by Regions
  2.3.1 Market Analysis of Biosimilar Insulin in Europe 2013-2017
  2.3.2 Market Analysis of Biosimilar Insulin in Middle East 2013-2017
  2.3.3 Market Analysis of Biosimilar Insulin in Africa 2013-2017
2.4 Market Development Forecast of Biosimilar Insulin in EMEA 2018-2023
  2.4.1 Market Development Forecast of Biosimilar Insulin in EMEA 2018-2023
  2.4.2 Market Development Forecast of Biosimilar Insulin by Regions 2018-2023

CHAPTER 3 EMEA MARKET STATUS AND FORECAST BY TYPES

3.1 Whole EMEA Market Status by Types
  3.1.1 Consumption Volume of Biosimilar Insulin in EMEA by Types
  3.1.2 Revenue of Biosimilar Insulin in EMEA by Types
3.2 EMEA Market Status by Types in Major Countries
  3.2.1 Market Status by Types in Europe
  3.2.2 Market Status by Types in Middle East
  3.2.3 Market Status by Types in Africa
3.3 Market Forecast of Biosimilar Insulin in EMEA by Types

CHAPTER 4 EMEA MARKET STATUS AND FORECAST BY DOWNSTREAM INDUSTRY

4.1 Demand Volume of Biosimilar Insulin in EMEA by Downstream Industry
4.2 Demand Volume of Biosimilar Insulin by Downstream Industry in Major Countries
  4.2.1 Demand Volume of Biosimilar Insulin by Downstream Industry in Europe
  4.2.2 Demand Volume of Biosimilar Insulin by Downstream Industry in Middle East
  4.2.3 Demand Volume of Biosimilar Insulin by Downstream Industry in Africa
4.3 Market Forecast of Biosimilar Insulin in EMEA by Downstream Industry

CHAPTER 5 MARKET DRIVING FACTOR ANALYSIS OF BIOSIMILAR INSULIN

5.1 EMEA Economy Situation and Trend Overview
5.2 Biosimilar Insulin Downstream Industry Situation and Trend Overview

CHAPTER 6 BIOSIMILAR INSULIN MARKET COMPETITION STATUS BY MAJOR PLAYERS IN EMEA

6.1 Sales Volume of Biosimilar Insulin in EMEA by Major Players
6.2 Revenue of Biosimilar Insulin in EMEA by Major Players
6.3 Basic Information of Biosimilar Insulin by Major Players
  6.3.1 Headquarters Location and Established Time of Biosimilar Insulin Major Players
  6.3.2 Employees and Revenue Level of Biosimilar Insulin Major Players
6.4 Market Competition News and Trend
  6.4.1 Merger, Consolidation or Acquisition News
  6.4.2 Investment or Disinvestment News
  6.4.3 New Product Development and Launch

CHAPTER 7 BIOSIMILAR INSULIN MAJOR MANUFACTURERS INTRODUCTION AND MARKET DATA

7.1 Pfizer
  7.1.1 Company profile
  7.1.2 Representative Biosimilar Insulin Product
  7.1.3 Biosimilar Insulin Sales, Revenue, Price and Gross Margin of Pfizer
7.2 Biogenomics
  7.2.1 Company profile
  7.2.2 Representative Biosimilar Insulin Product
  7.2.3 Biosimilar Insulin Sales, Revenue, Price and Gross Margin of Biogenomics
7.3 Eli Lilly
  7.3.1 Company profile
  7.3.2 Representative Biosimilar Insulin Product
  7.3.3 Biosimilar Insulin Sales, Revenue, Price and Gross Margin of Eli Lilly
7.4 Gan&Lee Pharmaceuticals
  7.4.1 Company profile
  7.4.2 Representative Biosimilar Insulin Product
  7.4.3 Biosimilar Insulin Sales, Revenue, Price and Gross Margin of Gan&Lee Pharmaceuticals
7.5 Geropharm
  7.5.1 Company profile
  7.5.2 Representative Biosimilar Insulin Product
  7.5.3 Biosimilar Insulin Sales, Revenue, Price and Gross Margin of Geropharm
7.6 Julphar Gulf Pharmaceutical Industries
  7.6.1 Company profile
  7.6.2 Representative Biosimilar Insulin Product
  7.6.3 Biosimilar Insulin Sales, Revenue, Price and Gross Margin of Julphar Gulf Pharmaceutical Industries
7.7 Paras Biopharmaceuticals
  7.7.1 Company profile
  7.7.2 Representative Biosimilar Insulin Product
  7.7.3 Biosimilar Insulin Sales, Revenue, Price and Gross Margin of Paras Biopharmaceuticals
7.8 Samsung Bioepis
  7.8.1 Company profile
  7.8.2 Representative Biosimilar Insulin Product
  7.8.3 Biosimilar Insulin Sales, Revenue, Price and Gross Margin of Samsung Bioepis
7.9 Sedico
  7.9.1 Company profile
  7.9.2 Representative Biosimilar Insulin Product
  7.9.3 Biosimilar Insulin Sales, Revenue, Price and Gross Margin of Sedico
7.10 Wockhardt
  7.10.1 Company profile
  7.10.2 Representative Biosimilar Insulin Product
  7.10.3 Biosimilar Insulin Sales, Revenue, Price and Gross Margin of Wockhardt
7.11 Teva Pharmaceuticals
  7.11.1 Company profile
  7.11.2 Representative Biosimilar Insulin Product
  7.11.3 Biosimilar Insulin Sales, Revenue, Price and Gross Margin of Teva Pharmaceuticals

CHAPTER 8 UPSTREAM AND DOWNSTREAM MARKET ANALYSIS OF BIOSIMILAR INSULIN

8.1 Industry Chain of Biosimilar Insulin
8.2 Upstream Market and Representative Companies Analysis
8.3 Downstream Market and Representative Companies Analysis

CHAPTER 9 COST AND GROSS MARGIN ANALYSIS OF BIOSIMILAR INSULIN

9.1 Cost Structure Analysis of Biosimilar Insulin
9.2 Raw Materials Cost Analysis of Biosimilar Insulin
9.3 Labor Cost Analysis of Biosimilar Insulin
9.4 Manufacturing Expenses Analysis of Biosimilar Insulin

CHAPTER 10 MARKETING STATUS ANALYSIS OF BIOSIMILAR INSULIN

10.1 Marketing Channel
  10.1.1 Direct Marketing
  10.1.2 Indirect Marketing
  10.1.3 Marketing Channel Development Trend
10.2 Market Positioning
  10.2.1 Pricing Strategy
  10.2.2 Brand Strategy
  10.2.3 Target Client
10.3 Distributors/Traders List

CHAPTER 11 REPORT CONCLUSION

CHAPTER 12 RESEARCH METHODOLOGY AND REFERENCE

12.1 Methodology/Research Approach
  12.1.1 Research Programs/Design
  12.1.2 Market Size Estimation
  12.1.3 Market Breakdown and Data Triangulation
12.2 Data Source
  12.2.1 Secondary Sources
  12.2.2 Primary Sources
12.3 Reference
Skip to top


Ask Your Question

Biosimilar Insulin-EMEA Market Status and Trend Report 2013-2023
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: